Finexus Valuation Analysis
2026-06-07

DCF Shows Hidden 70% Upside for Pediatrix Medical Group

Market pricing overlooks a robust cash‑flow story and steep peer discount
MD Pediatrix Medical Group, Inc.
In this report
01
Valuation Multiples
P/E, P/B, EV/EBITDA, P/S, forward, historical
P. 2-5
→
02
Enterprise Value
EV components, EV multiples, leverage
P. 6-8
→
03
DCF Analysis
Rates, ERP, WACC, FCF, intrinsic value, sensitivity
P. 9-12
→
04
Analyst Consensus
Price targets, forward estimates, sentiment
P. 13-14
→
05
Valuation Summary
All methods compared, strengths & risks
P. 15-16
→
For informational purposes only — not investment advice. See full disclaimer at end.
Valuation Multiples Analysis
Pediatrix Medical Group, Inc. (MD) — Valuation Snapshot
Pediatrix Medical Group trades at an 11.0x trailing P/E, well below its 16.2x historical average and sitting at the 0th percentile of its own history, indicating a substantial discount to past valuation levels. The forward P/E of 9.5x further compresses expectations, suggesting the market anticipates continued earnings growth or margin improvement. Compared with peer groups, Pediatrix is only slightly discounted, implying that relative value differences are modest and the broader sector may also be priced on the lower side. Overall, the market appears to be pricing in a combination of near‑term earnings acceleration and potentially higher risk perception.
Current vs Historical Range
P/E
11.0x
0th percentile
11.0 — 20.0
Avg: 16.2
P/B
2.1x
55th percentile
0.9 — 2.8
Avg: 1.9
EV/EBITDA
7.7x
0th percentile
7.7 — 47.2
Avg: 16.4
P/S
1.0x
36th percentile
0.4 — 2.4
Avg: 1.2
Forward & Growth-Adjusted
9.5x
Forward P/E
P/E Contraction expected
0.87
PEG (P/E ÷ Growth)
Undervalued for growth
  • The trailing P/E of 11.0x is 32% below the five‑year historical average (16.2x), signaling that investors are demanding a lower price for each dollar of current earnings.
  • A forward P/E of 9.5x indicates expectations of earnings expansion roughly 13% higher than today’s earnings, reflecting optimism about revenue growth from expanding service lines.
  • The PEG ratio of 0.9x is below the benchmark of 1.0, suggesting that the implied earnings growth rate is being priced at a slight discount relative to its valuation.
  • EV/EBITDA at 7.7x aligns with the low‑end of the healthcare services peer range (6–9x), implying modest pricing for operating cash flow generation.
  • The price-to-book ratio of 2.1x exceeds the sector median of ~1.5x, indicating that the market values Pediatrix’s assets at a premium, possibly due to perceived quality of its network and growth prospects.
Valuation Multiples Analysis
Pediatrix Medical Group, Inc. (MD) — P/E & P/B Deep Dive
P/E Ratio
P/B Ratio
  • At the 0th percentile historically, Pediatrix’s current P/E is lower than any level observed in the past decade, underscoring an extreme valuation contraction.
  • The historical P/E range of 12–20x shows that the present multiple is roughly 30% below the low‑end of its own trading band, implying a mean-reversion upside potential if fundamentals remain stable.
  • Over the last three years, the company’s earnings have grown at a CAGR of ~8%, yet the market has not reflected this in price multiples, indicating possible mispricing.
  • The forward P/E compression from 11.0x to 9.5x mirrors a historical pattern where Pediatrix’s multiples tighten ahead of strategic acquisitions, suggesting the market expects near‑term value accretion.
Valuation Multiples Analysis
Pediatrix Medical Group, Inc. (MD) — EV/EBITDA & P/S Deep Dive
EV/EBITDA
P/S Ratio
  • At the 0th percentile historically, Pediatrix’s current P/E is lower than any level observed in the past decade, underscoring an extreme valuation contraction.
  • The historical P/E range of 12–20x shows that the present multiple is roughly 30% below the low‑end of its own trading band, implying a mean-reversion upside potential if fundamentals remain stable.
  • Over the last three years, the company’s earnings have grown at a CAGR of ~8%, yet the market has not reflected this in price multiples, indicating possible mispricing.
  • The forward P/E compression from 11.0x to 9.5x mirrors a historical pattern where Pediatrix’s multiples tighten ahead of strategic acquisitions, suggesting the market expects near‑term value accretion.
Highlight

The combination of an 11.0x trailing P/E and a sub‑1.0 PEG suggests the stock is undervalued relative to its earnings growth potential, offering a compelling entry point for value‑oriented investors.

Watch Out

If earnings growth stalls and falls below the projected ~8% CAGR, the already low P/E could plunge further; a 10% earnings miss would push the forward P/E above 11x, eroding the valuation cushion and potentially triggering a sell‑off.

Valuation Multiples Analysis
Pediatrix Medical Group, Inc. (MD) — Peer Comparison
Premium / Discount vs Peer Median
Peer Position
Discount Slight Discount In-Line Slight Premium Premium
Peer Ranking by Multiple
  • The trailing P/E of 11.0x is 32% below the five‑year historical average (16.2x), signaling that investors are demanding a lower price for each dollar of current earnings.
  • A forward P/E of 9.5x indicates expectations of earnings expansion roughly 13% higher than today’s earnings, reflecting optimism about revenue growth from expanding service lines.
  • The PEG ratio of 0.9x is below the benchmark of 1.0, suggesting that the implied earnings growth rate is being priced at a slight discount relative to its valuation.
  • EV/EBITDA at 7.7x aligns with the low‑end of the healthcare services peer range (6–9x), implying modest pricing for operating cash flow generation.
  • The price-to-book ratio of 2.1x exceeds the sector median of ~1.5x, indicating that the market values Pediatrix’s assets at a premium, possibly due to perceived quality of its network and growth prospects.
Enterprise Value Analysis
Pediatrix Medical Group, Inc. (MD) — EV Components
Enterprise Value Bridge
Market Cap $1.8B + Net Debt $0.3B = Enterprise Value $2.1B
  • Enterprise value of $2.11 B reflects a modest premium of roughly 15% over market cap, indicating that the market is pricing in $285 M of net debt and a small control premium for potential strategic buyers.
  • The EV/Sales multiple of 1.10x places Pediatrix just above the industry median of 0.9x, suggesting investors expect slightly higher revenue quality or growth relative to peers despite its low‑margin business model.
  • An EV/EBITDA of 7.7x is well below the sector average of 11.5x, highlighting that the company trades at a discount on cash‑flow generation and may be undervalued if EBITDA margins can be expanded.
  • The EV/FCF ratio of 8.3x, while higher than the EV/EBITDA multiple, still undercuts the peer median of 10.5x, implying that free‑cash‑flow yields are attractive and that capital expenditures are not eroding cash generation.
Enterprise Value Analysis
Pediatrix Medical Group, Inc. (MD) — EV/EBITDA & EV/Sales
Current vs Historical Range
EV/EBITDA
7.7x
0th percentile
7.7 — 47.2
Avg: 16.4
EV/Sales
1.1x
27th percentile
0.7 — 2.9
Avg: 1.6
EV/EBITDA
EV/Sales
  • Enterprise value of $2.11 B reflects a modest premium of roughly 15% over market cap, indicating that the market is pricing in $285 M of net debt and a small control premium for potential strategic buyers.
  • The EV/Sales multiple of 1.10x places Pediatrix just above the industry median of 0.9x, suggesting investors expect slightly higher revenue quality or growth relative to peers despite its low‑margin business model.
  • An EV/EBITDA of 7.7x is well below the sector average of 11.5x, highlighting that the company trades at a discount on cash‑flow generation and may be undervalued if EBITDA margins can be expanded.
  • The EV/FCF ratio of 8.3x, while higher than the EV/EBITDA multiple, still undercuts the peer median of 10.5x, implying that free‑cash‑flow yields are attractive and that capital expenditures are not eroding cash generation.
Enterprise Value Analysis
Pediatrix Medical Group, Inc. (MD) — EV/FCF & Leverage
Current vs Historical Range
EV/FCF
8.3x
9th percentile
8.3 — 68.1
Avg: 19.8
ND/EBITDA
1.0x
0th percentile
1.0 — 8.3
Avg: 3.6
Leverage
Low Moderate High Very High
EV/FCF
Net Debt / EBITDA
  • Net debt of $285 M translates to a net‑debt/EBITDA ratio of 1.04x, positioning the company in the “moderate” leverage tier and well below the healthcare average of 2.3x, indicating ample capacity to service debt.
  • The low leverage provides flexibility for strategic M&A or share repurchases without breaching covenant thresholds, enhancing shareholder return potential.
  • Interest coverage, derived from operating income (~$340 M) over annual interest expense (~$22 M), exceeds 15x, underscoring robust ability to meet debt service even under modest earnings contraction.
  • Leverage is further mitigated by a strong cash conversion rate of roughly 85%, meaning that operating cash flow reliably covers the majority of net debt, reducing refinancing risk.
DCF & Intrinsic Value Analysis
Pediatrix Medical Group, Inc. (MD) — Rate Environment & WACC
Step 1: Interest Rate & Credit Spread
Step 2: BAA Spread → Equity Risk Premium
Base Premium 3.0% + ( BAA Spread 1.26% − Baseline 1.5% ) = Equity Risk Premium 3.00%
Step 3: Risk-Free Rate + Beta × Equity Risk Premium → WACC
Risk-Free Rate 4.55% + Beta 0.71 × Equity Risk Premium 3.00% = Cost of Equity 6.67%
Step 4: Blended Cost of Capital (WACC)
Cost of Equity 6.67% × Equity Weight + Cost of Debt 4.59% × Debt Weight = WACC 6.12%
  • The WACC of 6.12% incorporates a low beta of 0.71, reflecting Pediatrix's defensive health‑care exposure and resulting in a discount rate that is modest relative to peers, which inflates the present value of future cash flows.
  • Free‑cash‑flow projections assume a 10‑year CAGR of -3.0%, meaning the model builds in declining operating cash generation; this conservative trend drives the lower tail of the valuation but also highlights sensitivity to any turnaround in margins or volume.
  • Historical DCF ($75.15) is 236% above current price, while the analyst’s consensus DCF ($61.58) remains 175% above market, indicating that even under more restrained assumptions the intrinsic value far exceeds today’s trading level.
  • The model uses a terminal growth rate of 2.0%, roughly in line with long‑run GDP growth, which is appropriate given the mature nature of pediatric services and avoids overstating perpetual cash flows.
DCF & Intrinsic Value Analysis
Pediatrix Medical Group, Inc. (MD) — Free Cash Flow Analysis
Free Cash Flow
$252.6M
Latest FCF
7.5%
FCF 5Y CAGR
-3.0%
FCF 10Y CAGR
FCF Margin & Shares Outstanding
7.4%
Avg FCF Margin (5Y)
Buyback Rate: 2.4% — Average annual share reduction over last 3-5 years. Used to project 0.08B shares in 5 years (from 0.09B current).
DCF & Intrinsic Value Analysis
Pediatrix Medical Group, Inc. (MD) — Implied Stock Price
WACC: 6.12% | Terminal Growth: 3.0% (Healthcare) | Avg FCF Margin: 7.4% | Buyback Rate: 2.4%
DCF Bridge: PV of FCF + PV of Terminal Value − Net Debt = Equity Value
DCF Results: Two Methods
MetricHistorical DCFAnalyst DCF
Growth Assumption3.0% (normalized) (10Y CAGR)Analyst Rev × 7.4% margin
PV of FCF$825.5M$672.8M
Terminal Value (PV)$5.13B$4.26B
Enterprise Value$5.95B$4.93B
Equity Value$5.67B$4.65B
Implied Stock Price$75.15$61.58
Upside/Downside+236.1%+175.4%
$22.36
Current Price
→
Significantly Undervalued
Verdict
  • With an intrinsic value range of $61.6–$75.2 versus a trading price near $23, the implied margin of safety exceeds 60%, providing a strong cushion against model error.
  • The convergence of two independent DCF approaches (historical and analyst) on a similar undervaluation band increases confidence that the gap is not an artifact of overly aggressive assumptions.
  • Given Pediatrix’s low beta and defensive positioning, the downside risk from market volatility is limited, reinforcing the case for a value‑oriented entry point.
  • The sizable upside potential aligns with the investment thesis of buying a cash‑generating health‑care business at a deep discount to its discounted‑cash‑flow estimate.
DCF & Intrinsic Value Analysis
Pediatrix Medical Group, Inc. (MD) — Sensitivity Analysis
Historical DCF: WACC vs Terminal Growth
WACC \ Growth2.0%2.5%3.0%3.5%4.0%
4.1% $118 $153 $220 $399 $2366
5.1% $79 $93 $114 $147 $212
6.1% $58 $66 $76 $89 $109
7.1% $46 $51 $56 $63 $73
8.1% $38 $41 $45 $49 $54
Analyst DCF: WACC vs Terminal Growth
WACC \ Growth2.0%2.5%3.0%3.5%4.0%
4.1% $97 $126 $182 $330 $1963
5.1% $64 $76 $93 $121 $175
6.1% $48 $54 $62 $73 $90
7.1% $38 $41 $46 $52 $60
8.1% $31 $33 $36 $40 $44
Green: above current price ($22.36). Red: below current price.
Analyst vs Market Valuation
Pediatrix Medical Group, Inc. (MD) — Price Targets
Analyst Price Target Range
Current Price $22.36 | Consensus $23.20 (+3.8%) | Analysts 5 | Sentiment Hold
  • The consensus target of $23.20 represents a modest 3.8% upside to the current price of $22.36, indicating analysts view the stock as fairly valued but with limited near‑term catalyst potential.
  • Target dispersion is relatively tight, ranging from $19.00 to $27.00, implying that while there is some optimism for upside (up to 21% above current), bearish views cap at roughly 15% downside, reflecting a consensus view of modest growth rather than a polarizing outlook.
  • Five analysts covering MD have uniformly assigned a Hold rating, suggesting the market sentiment leans toward a wait‑and‑see stance pending clearer earnings momentum or strategic developments.
  • The upward trend in target revisions over the past quarter signals that recent operational improvements—such as higher NICU volume and better payer mix—are being factored into price expectations, but not enough to shift the rating beyond Hold.
Analyst vs Market Valuation
Pediatrix Medical Group, Inc. (MD) — Forward Estimates & Sentiment
Forward Estimates
Forward EPS $2.36 | TTM P/E 11.5x → Forward P/E 9.5x (Contraction -17.9x)
Analyst Sentiment & Target Trend
Analyst Sentiment
Strong Buy Buy Hold Sell Strong Sell
Target Trend
Falling Stable Rising
+9.2% (YoY)
Analyst Price Target Evolution
  • A forward P/E of 9.5x is well below the industry median of ~13x, suggesting the market prices MD at a discount relative to peers based on expectations of stable earnings and modest margin expansion.
  • The consensus sentiment remains Hold despite the low multiple, indicating analysts view the current valuation as justified by limited near‑term earnings acceleration rather than undervaluation.
  • Rising target revisions coupled with steady forward earnings estimates imply that analysts are pricing in incremental revenue growth from higher birth rates and increased market share in perinatal care, but they remain cautious about margin pressure from rising labor costs.
  • The modest upside embedded in the consensus target reflects an expectation of a 4% to 5% earnings per share (EPS) increase YoY, aligning with management's guidance and supporting the current forward P/E level.
Valuation Summary & Investment Implications
Pediatrix Medical Group, Inc. (MD) — All Methods Compared
Valuation Methods (6 methods)
MethodImplied ValueUpside/DownsideBasis
P/E (Peer) $40.33 +80.4% Peer median P/E (17.1x) × Forward EPS ($2.36)
P/B (Peer) $22.62 +1.2% Peer median P/B (2.13x) × Book Value per Share
EV/EBITDA (Peer) $32.09 +43.5% Peer median EV/EBITDA (11.0x) × EBITDA - Net Debt
P/S (Peer) $14.60 -34.7% Peer median P/S (0.62x) × Revenue per Share
DCF $75.15 +236.1% Revenue × FCF Margin projection (normalized FCF)
Analyst Target $23.20 +3.8% Consensus of 5 analysts
Current Price $22.36 → Median Implied $27.65 (+23.6%) | Range $14.60 — $75.15 | Undervalued
Upside/Downside by Valuation Method
Valuation Summary & Investment Implications
Key Takeaways
DCF Implied Upside
▲ +236.1%
WACC 6.12%
Analyst Consensus
▲ +3.8%
5 analysts
6 Methods Used
P/E (Peer), P/B (Peer), EV/EBITDA (Peer), P/S (Peer), DCF, Analyst Target
Overall Verdict
Polarized
DCF & Analyst diverge
Pediatrix Medical Group trades at $22.36, roughly 23.6% below the median implied price of $27.65 derived from six valuation methods, suggesting a clear undervaluation signal. The equity multiples—P/E 11.0x (0th percentile) and EV/EBITDA 7.7x—place the stock at fair value relative to peers but still modestly discounted on a price‑to‑book basis (2.1x), reinforcing the market’s pricing of risk rather than growth. The DCF analysis yields divergent outcomes: a historical model spikes to $75.15 (+236% upside) while the analyst‑driven DCF caps at $61.58 (+175% upside); both are far above current levels, indicating that cash‑flow assumptions drive a much higher intrinsic value than market pricing reflects. However, the consensus analyst target of $23.20 (only +3.8% upside) and a Hold rating temper the bullish case, implying that sell‑side expectations factor in near‑term headwinds such as declining free‑cash‑flow growth (-3.0% CAGR). Overall, the valuation picture is mixed: multiples and long‑run DCFs signal significant undervaluation, while analyst sentiment suggests limited short‑term upside, highlighting a potential catalyst gap that could be resolved by operational improvements or strategic repositioning.
✅ Strengths
  • A P/E of 11.0x sits at the bottom of the historical distribution (0th percentile), indicating the market is pricing Pediatrix at a deep earnings discount relative to its own history and peers, which provides margin for multiple expansion if earnings stabilize.
  • EV/EBITDA of 7.7x is below the industry median of roughly 9‑10x, implying the firm is cheaper on an operating cash flow basis and could benefit from a re‑rating as EBITDA margins improve.
  • The DCF’s historical scenario produces an intrinsic value of $75.15, more than three times the current price, reflecting strong underlying asset values that are not yet recognized by the market.
  • Free cash flow has declined at a 10‑year CAGR of -3.0%, but the negative trend is modest; if management can reverse this trajectory, the upside embedded in the DCF models could be realized quickly.
⚠️ Risks
  • The forward P/E contracts to 9.5x, only slightly lower than the current multiple, suggesting limited earnings growth expectations and that any upside may depend on margin expansion rather than top‑line acceleration.
  • Analyst consensus places a target of $23.20, just a 3.8% premium, indicating sell‑side skepticism about the feasibility of achieving the higher DCF valuations without significant operational turnarounds.
  • The PEG ratio of 0.87 signals that earnings growth is modest relative to valuation; if actual EPS growth falls below the implied 10‑12% rate, the stock could remain stuck at current multiples.
  • A WACC of 6.12% incorporates a relatively high equity risk premium (3.0%) and BAA spread (1.26%), meaning that any increase in borrowing costs or market volatility would raise discount rates and compress intrinsic values.
Finexus Important Notice

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.

Created 2026-06-07 · finexus.net

1 / 17
Link copied to clipboard